论文部分内容阅读
目的探讨恶性胸腹腔积液DNA倍体分析在其治疗效果评价中的作用。方法将抽取的胸腹腔积液50~100 ml用流式细胞仪做DNA倍体分析,根据治疗过程所测得的非整体细胞所占的比率变化来评价治疗效果。结果 48例患者初次DNA倍体分析阳性39例,阳性率81.3%,对初次分析阳性者在每次灌注化疗药物前做DNA倍体分析,29例三次灌注后转为阴性,积液又极少;6例四次灌注后转阴但积液量仍较多需再灌注白介素-2(IL-2)或激素;4例四次灌注后仍为阳性给予更换化疗药物。结论根据非整体细胞所占的比率变化评价疗效,如果多次灌药非整体倍细胞数比率仍较高说明肿瘤细胞已耐药,应及时换药,如治疗后倍体分析转阴性积液仍较多,可停止灌注化疗药物,继续应用灌注IL-2或激素。
Objective To investigate the role of DNA ploidy analysis of malignant pleural and peritoneal effusion in the evaluation of its therapeutic effect. Methods 50-100 ml pleural and peritoneal effusions were collected for DNA ploid analysis by flow cytometry. The therapeutic effect was evaluated according to the ratio of non-mononuclear cells in the course of treatment. Results 48 cases of primary DNA ploidy analysis was positive in 39 cases, the positive rate of 81.3%, positive for the first time before each infusion of chemotherapy drugs do DNA ploidy analysis, 29 cases of three perfusion turned negative, very few effusion ; 6 cases of reperfusion after four perfusion, but the fluid still more need to reperfusion interleukin-2 (IL-2) or hormone; four cases were still positive after four perfusion of chemotherapy drugs. Conclusion According to the ratio of non-integral cells to evaluate the effect of changes in the ratio, if the number of non-multiples of irrigation times the number of cells is still high that the drug-resistant tumor cells should be timely dressing, such as the treatment of ploidy after negative fluid transfer is still More, stop chemotherapy drugs, continue to use perfusion of IL-2 or hormone.